Guided Therapeutics, Inc.
GTHP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $98 | $13 | $81 |
| % Growth | -92.9% | 653.8% | -84% | – |
| Cost of Goods Sold | $5 | $62 | $81 | $61 |
| Gross Profit | $2 | $36 | -$68 | $20 |
| % Margin | 28.6% | 36.7% | -523.1% | 24.7% |
| R&D Expenses | $526 | $228 | $77 | $69 |
| G&A Expenses | $1,297 | $2,997 | $3,007 | $2,172 |
| SG&A Expenses | $1,584 | $3,265 | $3,188 | $2,313 |
| Sales & Mktg Exp. | $287 | $268 | $181 | $141 |
| Other Operating Expenses | $0 | $0 | $16 | $0 |
| Operating Expenses | $2,110 | $3,493 | $3,265 | $2,382 |
| Operating Income | -$2,108 | -$3,457 | -$3,333 | -$2,362 |
| % Margin | -30,114.3% | -3,527.6% | -25,638.5% | -2,916% |
| Other Income/Exp. Net | -$309 | -$32 | -$1,008 | $292 |
| Pre-Tax Income | -$2,417 | -$3,489 | -$4,341 | -$2,070 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,417 | -$3,489 | -$4,341 | -$2,070 |
| % Margin | -34,528.6% | -3,560.2% | -33,392.3% | -2,555.6% |
| EPS | -0.045 | -0.074 | -0.15 | -0.18 |
| % Growth | 38.5% | 51% | 16.7% | – |
| EPS Diluted | -0.045 | -0.074 | -0.15 | -0.18 |
| Weighted Avg Shares Out | 57,339 | 51,131 | 32,505 | 13,377 |
| Weighted Avg Shares Out Dil | 57,339 | 51,131 | 32,505 | 13,377 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $6 | $0 | $0 |
| Interest Expense | $381 | $278 | $582 | $1,150 |
| Depreciation & Amortization | $95 | $85 | $72 | $1 |
| EBITDA | -$1,941 | -$3,126 | -$3,687 | -$919 |
| % Margin | -27,728.6% | -3,189.8% | -28,361.5% | -1,134.6% |